Effect of Hyaluronic Acid and Pluronic-F68 on the Surface Properties of Foam as a Delivery System for Polidocanol in Sclerotherapy

• Main Authors: Teresa del Castillo-Santaella (Author), Yan Yang (Author), Inmaculada Martínez-González (Author), María José Gálvez-Ruiz (Author), Miguel Ángel Cabrerizo-Vílchez (Author), Juan Antonio Holgado-Terriza (Author), Fernando Selles-Galiana (Author), Julia Maldonado-Valderrama (Author)
• Format: Book
• Published: MDPI AG, 2020-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.3390/pharmaceutics12111039; 1999-4923
• Keywords: polidocanol; foam; sclerotherapy; hyaluronic acid; poloxamer; surface tension; Pharmacy and materia medica; RS1-441
• Source: Pharmaceutics, Vol 12, Iss 11, p 1039 (2020)

The use of foams to deliver bioactive agents and drugs is increasing in pharmaceutics. One example is the use of foam as a delivery system for polidocanol (POL) in sclerotherapy, with the addition of bioactive compounds to improve the delivery system being a current subject of study. This work shows the influence of two bioactive additives on the structure and stability of POL foam: hyaluronic acid (HA) and Pluronic-F68 (F68). HA is a natural non-surface-active biopolymer present in the extracellular matrix while F68 is a surface-active poloxamer that is biocompatible with plasma-derived fluids. Both additives increase the bulk viscosity of the sample, improving foam stability. However, HA doubled and F68 quadruplicated the foam half lifetime of POL. HA reduced the size and polydispersity of the bubble size distribution and increased the surface elasticity with respect to POL. Both facts have a positive impact in terms of foam stability. F68 also altered bubble structure and increased surface elasticity, again contributing to the enhancement of foam stability. The surface characterization of these systems is important, as in foam sclerotherapy it is crucial to assure the presence of POL at the surface of the bubbles in order to deliver the sclerosant agent in the target vein.